Unlock instant, AI-driven research and patent intelligence for your innovation.

Combined drug delivery system using CpG oligodeoxynucleotide and beta-1,3-glucan, method and application

A technology of oligodeoxynucleotide and drug delivery system, which is applied in the field of combined drug delivery system, can solve problems such as poor cancer effect, and achieve the effect of good tumor suppression effect, good effect and controllable quality

Inactive Publication Date: 2021-06-29
NANJING LUYE PHARMA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The purpose of the present invention is to solve the problem that the combination of CpG oligodeoxynucleotide and β-1,3-glucan is not effective in treating cancer, and provides a CpG oligodeoxynucleotide and β-1,3-glucan The combined drug delivery system has a significant anti-tumor effect, and it can exert the combined anti-tumor effect of CpG oligodeoxynucleotide and β-1,3-glucan better than the single drug or the combined drug of the compound, especially in advance Injection of β-1,3-glucan is more effective than administration of CpG oligodeoxynucleotide and β-1,3-glucan in inhibiting tumor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined drug delivery system using CpG oligodeoxynucleotide and beta-1,3-glucan, method and application
  • Combined drug delivery system using CpG oligodeoxynucleotide and beta-1,3-glucan, method and application
  • Combined drug delivery system using CpG oligodeoxynucleotide and beta-1,3-glucan, method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] 1. Drug: CpG oligodeoxynucleotide 1, sequence: 5'-tcgaacgttcgaacgttcgaacgttcgaat-3' (all phosphorothioated phosphodiester bonds), manufacturer: Guangzhou Ruibo Biotechnology Co., Ltd. β-1,3-glucan: Lentinan, manufacturer: Nanjing Luye Pharmaceutical Co., Ltd.

[0048] Excipients: Sodium Chloride, Manufacturer: Aladdin

[0049] Mannitol, manufacturer: Shijiazhuang Huaxu Pharmaceutical Co., Ltd.

[0050] 2. Animal: BALB / c mouse

[0051] 3. Cells: mouse colon cancer cell line CT-26 cells

[0052] 4. Dosing regimen:

[0053] (1) Control group:

[0054] Intratumoral injection of normal saline group, 50 μL / rat;

[0055] CpG oligodeoxynucleotide group: intratumoral injection of CpG oligodeoxynucleotide 1 (injection; excipient: sodium chloride), 50 μg per mouse, twice a week;

[0056] β-1,3-glucan group: intravenous injection of lentinan (freeze-dried preparation, reconstituted in normal saline; excipients: sodium chloride, mannitol), 2 mg / kg, three times a week.

[0057...

Embodiment 2

[0066] 1. Drug: CpG oligodeoxynucleotide 1, sequence: 5'-tcgaacgttcgaacgttcgaacgttcgaat-3' (all phosphorothioated phosphodiester bonds), manufacturer: Guangzhou Ruibo Biotechnology Co., Ltd. β-1,3-glucan: Lentinan, manufacturer: Nanjing Luye Pharmaceutical Co., Ltd.

[0067] Excipients: Sodium Chloride, Manufacturer: Aladdin

[0068] Mannitol, manufacturer: Shijiazhuang Huaxu Pharmaceutical Co., Ltd.

[0069] Cane Sugar: Production Producer: Merck

[0070] 2. Animal: BALB / c mouse

[0071] 3. Cells: mouse colon cancer cell line CT-26 cells

[0072] 4. Dosing regimen:

[0073] (1) Control group:

[0074] Intratumoral injection of normal saline group, 50 μL / rat;

[0075] CpG oligodeoxynucleotide group: Intratumoral injection of CpG oligodeoxynucleotide 1 (lyophilized preparation, reconstituted in normal saline; excipients: sucrose, sodium chloride), 50 μg per mouse, 3 times a week;

[0076] β-1,3-glucan group: intravenous injection of lentinan (lyophilized preparation, rec...

Embodiment 3

[0084] 1. Drug: CpG oligodeoxynucleotide 1, sequence: 5'-tcgaacgttcgaacgttcgaacgttcgaat-3' (all phosphorothioated phosphodiester bonds), manufacturer: Guangzhou Ruibo Biotechnology Co., Ltd. β-1,3-glucan: Lentinan, manufacturer: Nanjing Luye Pharmaceutical Co., Ltd.

[0085] Excipients: Sodium Chloride, Manufacturer: Aladdin

[0086] Mannitol, manufacturer: Shijiazhuang Huaxu Pharmaceutical Co., Ltd.

[0087] 2. Animal: BALB / c mouse

[0088] 3. Cells: mouse colon cancer cell line CT-26 cells

[0089] 4. Dosing regimen:

[0090] (1) Control group:

[0091] Intratumoral injection of normal saline group, 50 μL / rat;

[0092] CpG oligodeoxynucleotide group: Intratumoral injection of CpG oligodeoxynucleotide 1 (lyophilized preparation, reconstituted in normal saline; excipients: mannitol, sodium chloride), 25 μg per mouse, 4 times a week;

[0093] β-1,3-glucan group: intravenous injection of lentinan (lyophilized preparation, reconstituted in normal saline; excipients: sodium ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a combined drug delivery system using CpG oligodeoxynucleotide and beta-1,3-glucan, and belongs to the field of cancer immunotherapy. The combined drug delivery system using the CpG oligodeoxynucleotide and the beta-1,3-glucan has a remarkable tumor inhibition effect, can better play a combined tumor inhibition effect of the CpG oligodeoxynucleotide and the beta-1,3-glucan compared with single drug delivery or combined drug delivery of a compound, and especially has a better tumor inhibition effect than the tumor inhibition effect of the CpG oligodeoxynucleotide and the beta-1,3-glucan which are administered together when injecting the beta-1,3-glucan in advance.

Description

technical field [0001] The present invention relates to the field of cancer immunotherapy, in particular to a combined drug delivery system, method and application using CpG oligodeoxynucleotide and β-1,3-glucan. Background technique [0002] CpG oligodeoxynucleotides (CpG ODN) are short (approximately 20 base pairs), single-stranded synthetic DNA fragments containing immunostimulatory CpG motifs that can stimulate the body's innate immunity by activating Toll-like receptor 9 and the acquired immune system, mainly including the direct activation of B cells, dendritic cells, macrophages, antigen-presenting cells, etc.; the indirect activation of T cells and NK cells; Therefore, the CpG oligodeoxynucleotide (CpG ODN) has a strong potential application value in tumor immunotherapy. [0003] Four types of CpG oligodeoxynucleotides currently exist, each with different backbones, sequences, and immunostimulatory properties. Type A CpG oligodeoxynucleotides typically contain a pa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7115A61K31/716A61P35/00A61P37/04
CPCA61K31/7115A61K31/716A61P35/00A61P37/04
Inventor 程光张国喜孙慧萍徐凯田烽椿陈文忠张国敏
Owner NANJING LUYE PHARMA